Proposed Rule Offers Employers Optional Fertility Benefits, Sparks Debate on Access and Restrictions

The Centers for Medicare & Medicaid Services (CMS), an agency within the U.S. Department of Health and Human Services (HHS), has published a proposed rule that could introduce a new legal avenue for employers to provide supplemental fertility care benefits to their employees. This development, announced on May 13, 2026, has been framed by the current administration as an expansion of fertility coverage. However, a closer examination reveals that the proposed rule offers employers the option to provide such benefits, rather than mandating coverage. Crucially, it does not extend access to vital fertility treatments like in vitro fertilization (IVF) within public health insurance programs such as Medicaid, nor does it establish universal standards for the type of fertility care that could be covered.

The nuances of this proposed rule have ignited a complex discussion about the true scope of the administration’s commitment to reproductive healthcare access and the potential implications for individuals and couples seeking fertility assistance. While the stated intention is to facilitate employer-sponsored fertility benefits, critics argue that the optional nature of the provision and the lack of federal mandates for comprehensive coverage, particularly for IVF, fall short of addressing the significant financial and logistical barriers many face. Furthermore, concerns have been raised regarding the potential for employers to offer only "restricted IVF" or to adopt approaches to fertility health that may not align with evidence-based medical practices or the principles of reproductive autonomy.

Background: The Evolving Landscape of Fertility Benefits

The push for enhanced fertility benefits in the workplace has gained momentum in recent years, driven by several converging factors. Advances in assisted reproductive technologies (ART), including IVF, have made family-building possible for a growing number of individuals and couples struggling with infertility. Simultaneously, the rising cost of these treatments has placed them out of reach for many, even those with employer-sponsored health insurance. According to data from the National Infertility Association (ạo) RESOLVE, the average cost of one IVF cycle can range from $12,000 to $20,000, not including medications, which can add several thousand dollars more. Without insurance coverage, the cumulative cost of multiple cycles required for a successful pregnancy can be prohibitive, leading to significant financial strain and emotional distress.

Historically, fertility treatments have been largely excluded from standard health insurance plans. This exclusion has disproportionately affected women and LGBTQ+ individuals, who may face unique challenges in accessing fertility services. The increasing awareness of infertility as a medical condition, coupled with advocacy efforts from patient groups and fertility clinics, has spurred some employers to re-evaluate their benefits packages. As of 2023, a survey by the Employers Health Coalition indicated that approximately 40% of large employers offered some form of fertility benefit, a significant increase from previous years, but coverage varies widely in scope and accessibility.

The proposed rule by CMS aims to provide a clearer legal framework for employers looking to incorporate fertility benefits. It seeks to create an "excepted benefit" under the Employee Retirement Income Security Act (ERISA) for supplemental fertility care. This designation would allow employers to offer these benefits without triggering certain ERISA requirements that apply to comprehensive health plans, potentially simplifying the process for employers to implement and manage such programs.

The Proposed Rule: A Closer Look at the Details

The proposed rule, published in the Federal Register under document number 2026-09479, specifically addresses "Excepted Fertility Benefits." The core of the proposal is to allow employers to design and offer fertility benefits as a separate, supplemental package. This distinction is significant because it means these benefits would not be subject to the same mandates as primary health insurance. For example, the Affordable Care Act (ACA) requires most health plans to cover essential health benefits, but fertility treatments are not explicitly listed as one of these.

Crucially, the proposed rule grants employers the discretion to decide what types of fertility services will be covered. This is where a significant point of contention arises. The rule does not mandate coverage for specific treatments like IVF. Instead, it permits employers to choose to cover a broad spectrum of services, or to limit their offerings. This opens the door for employers to potentially offer benefits that focus on less invasive or more "natural" approaches to fertility, or to exclude or restrict access to advanced ART like IVF.

Concerns Regarding "Restricted IVF" and Reproductive Autonomy

A primary concern articulated by reproductive rights advocates is the potential for employers to opt for what is sometimes referred to as "restricted IVF" or to embrace approaches that may inadvertently discourage or limit access to scientifically proven fertility treatments. The original article highlights that under this proposed rule, employers could choose to cover only certain aspects of fertility care that might emphasize "lifestyle factors" as the primary cause of infertility, or that might frame infertility in ways that could be perceived as blaming individuals, particularly women, who are seeking to conceive.

Such approaches could manifest in several ways:

• Emphasis on Lifestyle Modifications: Employers might prioritize coverage for services that focus on diet, exercise, stress management, and alternative therapies, while offering limited or no coverage for diagnostic testing or ART like IVF.
• Exclusion of Specific ART: Coverage could be designed to exclude IVF altogether, or to include only a very limited number of cycles, or to apply stringent criteria for eligibility that exclude many individuals who could benefit from the technology.
• "Natural" Fertility Approaches: The benefits package could be geared towards promoting natural conception methods, which, while valuable for some, may not be sufficient for individuals with specific medical conditions that necessitate ART.

The original article quotes President Trump’s statement during the announcement of the new rule: "hopefully reduce the number of couples who ultimately need to resort to IVF." This statement has been interpreted by critics as indicative of a broader philosophy that views IVF as a last resort, rather than a critical and often necessary medical intervention for infertility. IVF is the most widely used and successful form of ART, enabling millions of individuals and couples to build their families. For many, it is not an option to be avoided, but a vital tool to overcome specific medical barriers to conception.

Broader Implications and Potential Impact

The implications of this proposed rule are far-reaching and depend heavily on how employers choose to implement it.

For Employees:

• Increased Access for Some: For employees whose employers opt for comprehensive fertility benefits, this rule could be a significant positive development, alleviating financial burdens and increasing access to family-building options.
• Limited or Ineffective Coverage for Others: Conversely, employees whose employers offer only restricted or superficial benefits may find themselves no better off than before. The optional nature of the rule means that disparities in access to fertility care based on employment could widen.
• Potential for Medical Gatekeeping: If employers are allowed to define eligibility criteria or the scope of covered services in ways that are not medically sound, it could lead to a form of medical gatekeeping, where access to necessary treatments is determined by employer policy rather than medical need.

For the Healthcare System:

• Fragmentation of Care: The creation of "excepted benefits" could lead to further fragmentation of healthcare coverage, making it more complex for individuals to navigate their benefits and understand what is covered.
• Innovation and Research: While not directly addressed by the rule, increased employer investment in fertility benefits could, in the long term, spur further innovation and research in ART. However, this is contingent on the breadth of coverage offered.

For Reproductive Rights and Policy:

• State-Level Variations: The federal government’s role in this area is limited. Many states already have mandates for fertility coverage, and the landscape of employer benefits will likely continue to be shaped by a combination of federal proposals, state laws, and employer decisions.
• Debate on "Right to Reproduce": The discussion surrounding fertility benefits touches upon broader societal debates about the right to reproduce, the definition of family, and the role of government and employers in supporting reproductive healthcare.

Expert Reactions and Analysis

While official statements from the administration highlight the proposed rule as a step forward, fertility advocacy groups and reproductive health organizations have offered a more cautious and critical perspective.

"This rule offers a glimmer of hope by providing a pathway for employers to offer fertility benefits," stated an analyst from a leading reproductive health policy think tank. "However, it is crucial to understand that this is an optional framework. It does not guarantee that employers will offer robust coverage, nor does it ensure that the most effective treatments, like IVF, will be accessible to all. The potential for employers to offer restrictive benefits that do not meet the needs of individuals facing infertility is a significant concern."

Dr. Anya Sharma, a fertility specialist with over two decades of experience, commented on the potential impact on patient care: "IVF is a complex medical procedure that requires personalized treatment plans. Limiting coverage to only certain aspects of fertility care, or prioritizing less evidence-based approaches, could be detrimental to patients who have already undergone extensive diagnostic evaluations and require the most effective interventions. We need coverage that is comprehensive and guided by medical necessity, not by employer preferences."

A spokesperson for a national infertility patient advocacy group emphasized the financial burden: "For many, infertility is a medical condition that requires significant financial investment. While this proposed rule is a step towards acknowledging that, it is not a solution. Without mandates for comprehensive coverage, especially for IVF, many individuals will continue to face insurmountable costs, forcing them to delay or abandon their dreams of starting a family. We urge the administration and employers to prioritize truly equitable access to fertility care."

The Path Forward: Public Comment and Future Implementation

The proposed rule is currently open for a public comment period, allowing stakeholders, including individuals, healthcare providers, employers, and advocacy groups, to submit their feedback to CMS. This feedback will be crucial in shaping the final rule. The administration will review these comments before issuing a final regulation.

The timeline for this process typically involves several months for comment review and a subsequent period for drafting and publishing the final rule. It is expected that the final rule will be published sometime in late 2026 or early 2027.

The ultimate success of this initiative in expanding access to fertility care will depend on several factors:

1. Employer Adoption: The extent to which employers choose to offer supplemental fertility benefits.
2. Scope of Coverage: The breadth and comprehensiveness of the benefits that employers decide to provide, particularly regarding IVF and other ART.
3. Future Legislative and Regulatory Actions: Potential for future legislation or regulatory changes at both the federal and state levels to mandate or further encourage comprehensive fertility coverage.

While the proposed rule represents a step in the ongoing conversation about reproductive healthcare access and employer responsibility, its effectiveness in truly expanding fertility coverage and ensuring equitable access to treatments like IVF remains a subject of considerable debate and will be closely watched by individuals, employers, and policymakers alike. The administration’s framing of the rule as an "expansion" is tempered by the understanding that it is an optional framework, leaving much of the impact to the discretion of individual employers.